Status:
UNKNOWN
Perioperative Safety of Bladder Hydrodistension in Patients on Antithrombotic Therapy
Lead Sponsor:
West China Hospital
Conditions:
Complication
Eligibility:
All Genders
18+ years
Brief Summary
After obtaining an institutional ethics approval (#2019186), we retrospectively reviewed patients with interstitial cystitis/bladder pain syndrome (IC/BPS) who underwent hydrodistension in our hospita...
Detailed Description
Study population. This retrospective study was performed in line with STROCSS guidelines. After obtaining an institutional ethics approval (#2019186), we retrospectively reviewed patients with IC/BPS ...
Eligibility Criteria
Inclusion
- Over 18 years old when signing an informed consent;
- Previously diagnosed with IC/BPS for a duration of \> 6 months;
- O'Leary-Sant Interstitial Cystitis Symptom and Problem Index scores over 18;
- Undergoing hydrodistension during the hospitalization;
- Patients with adequate medical records.
Exclusion
- General conditions 1) Currently diagnosed with cancer, or have previous history of cancer within the preceding 5 years; 2) Currently diagnosed with severe heart, lung, liver, kidney, or blood disorders; 3) Pregnant women.
- Urological symptoms 1) Have previous history of urinary infection (e.g., bacterial cystitis, bladder tuberculosis, urethritis, genital chlamydia infection, and genital herpes) within 12 weeks; 2) Currently diagnosed with any of following diseases, which had similar symptoms with IC/BPS.
- Bladder diseases (carcinoma, overactive bladder, neurogenic bladder, bladder stone, radiation cystitis)
- Urethral diseases (urethral diverticulum, urethral stricture, urethral stone)
- Gynaecological diseases (endometriosis, uterine fibroids, vaginitis, menopausal syndrome, pelvic organ prolapse)
- Others (neurogenic urinary frequency, polyuria) 3) Have previous history of augmentation cystoplasty or cystectomy; 4) Have previous history of chemical compound (such as cyclophosphamide) derived cystitis.
- Treatment related 1) History of the following therapies within 12 weeks: hydrodistension, intravesical laser therapy, intravesical electrical coagulation, transurethral resection, pelvic reconstructive surgery, nerve stimulation for pain relief; 2) Received intravesical instillation of any drugs within 12 weeks.
Key Trial Info
Start Date :
July 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 10 2024
Estimated Enrollment :
387 Patients enrolled
Trial Details
Trial ID
NCT05221944
Start Date
July 4 2019
End Date
April 10 2024
Last Update
September 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610041